Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus reuteri gl-104
- Development stage
- Unknown
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus reuteri GL-104 is a specific strain of probiotic bacterium originally classified under the genus *Lactobacillus* (now *Limosilactobacillus*) that is being developed for its potential health benefits, particularly in metabolic and immune modulation. Mechanistically, L. reuteri GL-104 acts by colonizing the intestinal tract, producing antimicrobial compounds (such as reuterin) that suppress pathogenic microorganisms, and modulating host glucose metabolism, as demonstrated by its ability to downregulate intestinal hexose transporters (SGLT1 and GLUT5) and reduce blood glucose in animal models. Preclinical studies show GL-104 improves glucose tolerance, attenuates diabetes-mediated organ injury, and offers immune regulatory potential. There is also evidence for its use in allergy, liver/kidney health, and oral care. The strain demonstrates high stability in gastric acid, strong adherence to intestinal cells, and is administered orally[3][4][8].
- Brand names
- bioflag lactobacillus reuteri gl-104
- Other names
- limosilactobacillus reuteri gl-104
02
Targets
SLC5A1 (Sodium Glucose Cotransporter 1)GLUT5 (Glucose transporter 5)
Beyond the preview
Go deeper on lactobacillus reuteri gl-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus reuteri gl-104.